search
Back to results

Protein Turnover in the Osteoarthritic Knee (KneeT)

Primary Purpose

Osteo Arthritis Knee, Protein Metabolism

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Preoperative protein supplementation
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Osteo Arthritis Knee

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Male and female patients scheduled for total knee arthroplasty
  • BMI between 18.5-30 kg/m2
  • Age > 18 years
  • Mentally competent, as judged by the treating physician
  • Functioning gastrointestinal tract, eligible for oral protein supplementation

Exclusion Criteria:

  • Corticosteroid injections less than 3 months prior to participation
  • Any medications know to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
  • Lactose intolerance
  • Insulin-dependent diabetes mellitus
  • Alcohol abuse
  • Rheumatoid arthritis
  • Peripheral artery disease Fontaine III or IV
  • COPD GOLD III or IV
  • Phenylketonuria
  • Surgical intervention in the past four weeks
  • Total parenteral nutrition at day of surgery
  • Neoadjuvant chemotherapy or radiotherapy
  • GFR <20 mL/min/1.73 m2
  • Osteoarthritis of the knee secondary to septic arthritis, osteonecrosis, fracture, OD, or malignant processes
  • Collagen disorders, e.g. Marfan and Ehler-Danlos
  • Any other medical condition that may interfere with the safety of the subjects or the outcome parameters, in the investigators judgement
  • Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol instructions
  • Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

Sites / Locations

  • Maastricht University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control group

Protein group

Arm Description

Subjects in the control group will receive no intervention.

Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.

Outcomes

Primary Outcome Measures

Change in tissue-specific protein synthesis rates
Fractional synthetic rates calculated based on tissue-free, plasma, and protein-bound tracer enrichments using stable isotope methodology and D2O dosing methodology.

Secondary Outcome Measures

Full Information

First Posted
January 24, 2017
Last Updated
October 18, 2023
Sponsor
Maastricht University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03037294
Brief Title
Protein Turnover in the Osteoarthritic Knee
Acronym
KneeT
Official Title
Protein Turnover in the Osteoarthritic Knee; the Impact of Preoperative Protein Intake and Intra-articular Corticosteroid Injections
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maastricht University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Osteoarthritis (OA) of the knee is a common cause of pain and disability, especially in people over the age of 65. In the current health care system both conservative (e.g. intra-articular injections with corticosteroids) and surgical (total knee replacement, TKR) treatment are applied. Although frequently used, certain effects of these treatments on protein metabolism remain unclear. It is well known that maintenance of different tissues is determined by a dynamic balance between protein synthesis and breakdown rates, with temporary changes in either protein synthesis or breakdown allowing net protein accretion or loss. Though protein supplementation has shown to be an effective nutritional strategy in stimulating muscle protein synthesis, it remains unclear to what extent other musculoskeletal tissues are able to respond to dietary protein supplementation. Therefore, the current study assesses the impact of preoperative protein supplementation on protein synthesis in different musculoskeletal tissues of the knee. Objective: To investigate the effect of preoperative protein supplementation on Hoffa's fat pad, synovium, tendon, bone, muscle, ligament, menisci, and cartilage protein synthesis of the OA knee. Study design: Randomized, parallel (two groups) study design. The intervention group will be compared to the control group. Study population: 24 adults with OA of the knee undergoing TKR. Intervention: Daily 40 g of pre-sleep protein two weeks before TKR or no intervention. Main study parameters/endpoints: Primary study parameters include protein synthesis rates and enrichments of Hoffa's fat pad, synovium, tendon, bone, muscle, ligament, menisci, and cartilage. Secondary parameters include whole-body protein synthesis, breakdown, oxidation, and net balance. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks involved in participating in this study are minimal. There are no potential effects known for the ingestion of protein. Muscle biopsies and tissue collection will be performed during the surgical procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteo Arthritis Knee, Protein Metabolism

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Subjects in the control group will receive no intervention.
Arm Title
Protein group
Arm Type
Experimental
Arm Description
Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
Intervention Type
Dietary Supplement
Intervention Name(s)
Preoperative protein supplementation
Intervention Description
Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
Primary Outcome Measure Information:
Title
Change in tissue-specific protein synthesis rates
Description
Fractional synthetic rates calculated based on tissue-free, plasma, and protein-bound tracer enrichments using stable isotope methodology and D2O dosing methodology.
Time Frame
Throughout the surgical procedure (stable isotope methodology) and during the 2-week preoperative period (D2O dosing methodology).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Male and female patients scheduled for total knee arthroplasty BMI between 18.5-30 kg/m2 Age > 18 years Mentally competent, as judged by the treating physician Functioning gastrointestinal tract, eligible for oral protein supplementation Exclusion Criteria: Corticosteroid injections less than 3 months prior to participation Any medications know to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications) Lactose intolerance Insulin-dependent diabetes mellitus Alcohol abuse Rheumatoid arthritis Peripheral artery disease Fontaine III or IV COPD GOLD III or IV Phenylketonuria Surgical intervention in the past four weeks Total parenteral nutrition at day of surgery Neoadjuvant chemotherapy or radiotherapy GFR <20 mL/min/1.73 m2 Osteoarthritis of the knee secondary to septic arthritis, osteonecrosis, fracture, OD, or malignant processes Collagen disorders, e.g. Marfan and Ehler-Danlos Any other medical condition that may interfere with the safety of the subjects or the outcome parameters, in the investigators judgement Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol instructions Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Floris Hendriks, MSc, MD
Phone
+31655522347
Email
f.hendriks@maastrichtuniversity.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Joey Smeets
Email
joey.smeets@maastrichtuniversity.nl
Facility Information:
Facility Name
Maastricht University Medical Center
City
Maastricht
ZIP/Postal Code
6229ER
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joey Smeets, MSc, MD
Phone
+31651363946
Email
joey.smeets@maastrichtuniversity.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Protein Turnover in the Osteoarthritic Knee

We'll reach out to this number within 24 hrs